Therapeutic modulation of the atherosclerotic process in human coronary arteries is now being attempted. A major aim of such attempts has been regression-that is, a diminution in the volume of atherosclerotic tissue. Many patients would, however, settle for stabilisation of their disease without further progression, and with a reduced risk of acute ischaemic events in the future. These may be more achievable aims.
Mechanisms of plaque growth Atherosclerotic plaques grow by the accumulation of lipid and the production of connective tissue matrix proteins, such as collagen, by smooth muscle cells. Lipid accumulation within the intima is a complex process. Plasma low density lipoproteins (LDL) freely enter and leave the intima across the endothelial surface. The first morphological change in the initiation of atherosclerosis in humans and in all animal models'2 is the migration of monocytes through an intact endothelial surface into the intima; these monocytes subsequently take up LDL and become lipid filled macrophage foam cells within the intima. Monocytes do not, however, have a receptor which enables them to take up native LDL within the intima. This paradox was resolved when it was realised that modification of the LDL by acetylation or oxidation leads to avid uptake by macrophages via the alternative scavenger receptor.' Oxidation of LDL occurs within or adjacent to endothelial cells and after binding of LDL to proteoglycans, within the intima. Oxidised LDL acts as a chemoattractant for monocytes, which it immobilises in the intima. It also acts as an activating factor and is cytotoxic as well as being ingested to form cholesterol filled foam cells. Oxidised lipid has been shown within the intima both in experimental and human atherosclerosis. 4 The progression of plaques5 is also associated with the accumulation of cholesteryl ester and cholesterol outside cells; this may be due either to release from dying foam cells or to direct extracellular conversion of LDL bound to the connective tissue matrix in the intima. 6 Smooth muscle cells will also take up low density lipoproteins but it is now apparent that most cells within the intima in which the cytoplasm is completely distended by lipid to form the classic foam cell are monocyte derived. 7 Removal of cholesterol from the intima is mediated by high density lipoproteins (HDL), which also freely enter the arterial wall across the endothelium.' They are less avidly bound by the connective tissue matrix and, being smaller than LDL particles, can move freely within the intima. HDL has an affinity to bind unesterified cholesterol; subsequently, within the HDL/cholesterol complex the enzyme lecithin cholesterol acyl transferase (LCAT) re-esterifies the cholesterol and the whole complex passes back into the plasma. Regression and inhibition in animal models of atherosclerosis Atherosclerosis in animals is induced by hyperlipidaemia, either produced by high fat diets or by metabolic defects in lipid metabolism. The Watanabe rabbit32 is deficient in the LDL receptor, and thus is analogous to human familial hypercholesterolaemia. The models can be criticised33 for testing cholesterol accumulation in the aorta rather than the development of atherosclerosis per se, with grossly unphysiological levels of consumption of dietary fat compared with human consumption, and for being very short term. The morphology of the lesions is often dominated by the presence of intracellular lipid rather than the extracellular lipid cores characteristic of human advanced plaques. Monkey' and pig models"4 which produce a disease in the long term more analogous to human atherosclerosis, particularly if associated with hypertension,35 are prohibitively expensive.
In animal models several drugs have been successful in retarding the development (drug given simultaneously with high lipid diet) or in causing regression (drug given after high lipid diet) of aortic lesions. They can be divided into those in which there is a significant lowering of plasma lipids and those which must have other mechanisms.
The models in which there was plasma lipid lowering include rabbits, pigs, dogs, chickens, pigeons, and monkeys.'6 Most of the studies compare the findings at necropsy in groups of animals treated differently, but in one the aorta was inspected at successive surgical explorations.3' All these models showed that it is possible to reduce cholesterol content, lesion size, and the total number of lesions. Cholesterol is removed from the plaques far faster than collagen. In some models the amount of collagen within plaques actually increases, and heavily cross-linked collagen resistant to collagenolysis is deposited in the regression phase. '8 3' In many animal models, unlike in humans, a high proportion of the cholesterol is contained within foam cells and is thus easily mobilised; in rhesus monkeys intra-arterial lipid was reduced within 4 weeks of the plasma lipid concentration retuming to normal.' The mechanism by which lowering plasma lipids causes inhibition or regression of atherosclerosis is by reducing the amount of LDL entering the intima, which allows the natural clearance pathway via HDL to predominate.
With probucol inhibition of atherosclerosis was much greater than expected for the observed reduction in plasma lipid concentration.4142 Carew and his colleagues showed that when plasma cholesterol decreased from a mean (SEM) of 761 (29) mg/dl to 618 (21) mg/ dl with lovastatin the percentage area of the aorta occupied by plaques was reduced from 40-6 (5 1)% to 27-5 (4 6)%.4' Probucol lowered plasma cholesterol (to 671 (20 7) mg/dl) less than lovastatin but reduced intimal involvement with atherosclerosis more (to 14 3 (2 1)%). The current view is that probucol prevents oxidation of LDL and therefore lipid uptake by macrophages within the intima to form foam cells.4' Prevention of lipid oxidation may also reduce monocyte recruitment into the intima.
Calcium antagonists can also influence atherosclerosis. Most studies indicate inhibition of lesion development with a range of calcium antagonists including verapamil, diltiazem, amlodipine, and nifedipine. 44 A dose dependent inhibition occurs both in the amount of cholesterol deposited and in the number of plaques in nifedipine treated NZ rabbits on a high lipid diet.4546 Results with nifedipine in the Watanabe rabbit, however, were more equivocal,47 and at least in one high fat diet model showed no effect of nifedipine. 48 In another study calcium antagonists in general were shown to alter atherogenesis in the aorta but not in the coronary arteries. 49 The mechanism by which calcium antagonists might inhibit the atherosclerotic process is far from certain but there is an embarrassing choice of possibilities. It seems likely there will be further demonstrations that drugs including antioxidants and anti-inflammatory agents have local effects on cells in the microenvironment ofthe plaque and these will be shown to be effective in modifying atherosclerosis in simple animal models.
Should this be so, they will be worthy of human studies.
Human studies of inhibition and regression of atherosclerosis In human coronary arteries high grade stenotic lesions contain large amounts of both collagen and calcium in addition to lipid; the relative proportion of lipid varies considerably from plaque to plaque, and is often very low. If the lessons of the animal models are correct, and lipid is removed rapidly but collagen is removed very slowly, significant regression of lesions causing high grade obstruction in man is unlikely other than over a long time.7' But the appearance of new lesions might be prevented, and lipid rich lesions might regress.
The propensity of plaques to become unstable and undergo fissuring and thrombosis is, however, related directly to the amount of extracellular lipid contained within the central core.'57273 A reduction in the amount of lipid with only a modest reduction in overall plaque volume might be accompanied by an increase in plaque stability with a decrease both in episodic plaque growth and a reduction in the risk of acute ischaemic events. For this reason, data both on the angiographic severity and on the clinical event rate are needed to assess any intervention in atherosclerosis.
Despite all the reservations concerning the ability ofthe angiogram to measure wall disease it remains the only technique available. Computerised image analysis has improved the subjective bias inherent in any visual interpretation of angiograms and must be considered the optimum method. Subset analysis can be made of the progression of lesions of different severity in the initial angiogram.
Given the interplaque variation in the proportions of the volume of tissue made up of collagen, lipid, and calcium it is unlikely that all lesions in any patient could regress at the same rate. The usual method of interpreting quantitative angiograpic data is to take the mean change for all the angiographically detected lesions. This has statistical convenience for comparing study groups but the mean changes are often very small in haemodynamic terms and may be biased by a large change in a single lesion. An alternative method is to give a visual score for progression or regression to each patient based on the number of lesions in that individual showing a recognisable change in lumen size and ranging from + 3 (change for better) through 0 (no change) to -3 (change for worse).
Since 1969 both angiography and the frequency of acute ischaemic events have been used as end points in trials of various methods to lower plasma lipids.
In 1976 a small study of 42 patients with femoral atherosclerosis showed that reduction in plasma lipids for one year was followed by angiographic improvement in six patients: on the other hand there was further luminal narrowing in 16 patients.74 A randomised controlled trial of 24 subjects with hyperlipidaemia and intermittent claudication showed that after treatment with cholestyramine, nicotinic acid, and clofibrate the number of femoral arterial segments that showed progression of atherosclerosis was reduced from 17 3% in the control group to 6-9% in the treated group. 75 Similar encouraging, though not startling, results were obtained by lowering plasma lipid concentrations in patients with coronary atherosclerosis. The National Heart Lung and Blood Institute study tested the effect ofcholestyramine on coronary atherosclerosis in hyperlipidaemic individuals and reported cholesterol concentrations reduced by 26%.76 Repeat angiography at five years in 59 treated patients and in 57 patients in a placebo group showed progression in 35% of those in the placebo group and in 25% in the test group; subclass analysis based on a range of angiographic variables suggested a favourable influence of treatment but clear statistical significance in the primary analysis was not achieved. A major difficulty in the study was that many individual patients showed both progression and regression at different sites within their coronary arteries.
Since these pioneer angiographic studies of regression other studies have been published. But there is no consensus on how to assess angiographic progression or regression in humans and trials of different methods both of deriving and analysing the measurements of stenoses are being reported. Direct comparison of these trials is therefore not easy.
In the Leiden Intervention Trial the plasma lipids were modified by diet alone; there was a modest reduction (mean (SD)) in total cholesterol (16-9 (1-4) mmol/l to 6-2 (1-3)) in 39 patients over two years without a control group.77 In 307 lesions found on initial angiography, ranging from minor to high grade, quantification was by a computer assisted analysis using the CAAS system. The mean (SD) percentage stenosis of all 307 lesions increased from 44-1 (31 6)% to 48-6 (30 9)% over the two year period. Thus overall there was a significant progression ofdisease. Of the 39 patients, 21 showed an increase in the mean percentage stenosis and 18 showed no increase. Comparison of the total cholesterol and total/HDL cholesterol ratio in the two groups showed significant differences. In those with lesions that progressed total cholesterol was 6 5 (1 5) and total cholesterol/HDL ratio 7 1 (1-7) as against [5] [6] [7] [8] (0-9) and 5 7 (1 2 46 -1%) in the control group. The changes were similar for lesions causing more than and less than 50% stenosis. Four of the patients in the test group showed progression and 18 showed regression while in the control group 11 either showed no change or progression and eight showed regression. In the Cholesterol Lowering Atherosclerosis Study (CLAS) 162 men undergoing coronary artery bypass grafting were randomised to treatment with colestipol and nicotinic acid or to placebo.7"79 Angiographic assessment was visual and used both grades of progression and regression ( + 3 to -3) for lesions present at the initial angiogram and the appearances of new lesions. Repeat angiography at two years showed a reduction in the number of new lesions that appeared in both the native vessels and the grafts. In 80 treated patients 8 (10%) developed new lesions in the native coronary arteries compared with 18 (22%) of the 82 patients in the placebo group. The figures at four years continued the same trend with the difference in the frequency ofnew lesions being 14-3% v 10-4%. According to the overall scoring system, at two years 45% of the drug treated group were static compared with 36-6% of the placebo group; progression had occurred in 38-8% of the treated group and 59-8% of the placebo group. Regression at two years was noted in 16-2% of the treated group compared with 3-6% of the placebo group; by four years the figures were 17-9 and 6-4% respectively. Despite all of the difficulties inherent in an overall scoring system of the state of the coronary artery tree the different patterns of progression in the drug and placebo group seemed well established.
The Programme on the Surgical Control of Hyperlipidaemias (POSCH) study compared 421 patients treated by partial ileal bypass with 417 patients in a randomly allocated control group.' The entry criteria were survival after one infarct and a plasma cholesterol concentration of at least 5-69 mmol/l. A mean reduction in total cholesterol of 23-2%, a reduction of LDL cholesterol of 37-7%, and an increase of 4 3% in HDL were achieved. Mean follow up was 9 7 years with the angiograms being graded visually by two observers according to an eight point scale ranging from + 3 to -3 from the CLAS study. Comparison of the angiograpic scores showed that 38-9% of patients in the treated group and 11 3% in the placebo group had remained static. In the treated group 54-8% showed progression but only 4-2% of these were graded as -3; in the placebo group 85% showed progression with 26-2% of them graded as -3. Regression was seen in 6 4% of the test and in 3-8% of the placebo group. The five patients with the best regression score ( + 3) all belonged to the placebo group-this result shows the unpredictability of atherosclerosis. The conclusion overall was that though there had been no regression, the rate of progression ofatherosclerosis had been significantly slowed.
In the Familial Atherosclerosis Treatment Study (FATS) 146 individuals with angiographic evidence of coronary atherosclerosis and at least one segment ofsignificant stenosis, a family history of coronary artery disease, and raised lipid concentrations were randomised to a control group, to lovastatin/colestipol, or to niacin/colestipol treatment.8' In the two treatment groups LDL concentrations fell significantly and plasma HLD concentrations rose. Angiography was repeated 30 months later. Angiograms were visually assessed and selected lesions manually traced to allow accurate measurement of the stenosis and lumen diameter. Nine standard proximal segments of the three main coronary branches were identified and the worst stenosis in each segment was measured. The average percentage stenosis of the worst lesion in all segments was calculated and regression or progression was expressed as the change in this value between the two sets of angiograms. In a second end point, regression and progression were defined for each patient individually by a change of at least 10% stenosis in at least one of the lesions. In this particular study only five of the 120 patients who completed the study had a mixture of progressing and regressing lesions; the rest could all be clearly classified as no change, regression, or progression. The 52 patients in the placebo group showed a mean increase of stenosis of 2 1% (SD 3-9%) while the niacin/colestipol group (n = 48) showed a decrease of -9% (3 0%) and the lovastatin/ colestipol group (n = 46) a decrease of -7% (5 3%). Forty six per cent of the placebo group progressed, 11% regressed, and 43% showed no change. The corresponding figures for the niacin/colestipol group were 25%, 39%, and 36% and for the lovastatin/colestipol group 21%, 32%, and 47%. One possible drawback in the study is that three of the four examples of striking angiographic regression illustrated could be regarded as acute unstable plaques in the initial study and the "regression" is caused by remodelling after organisation and lysis of thrombus.
Though these four recent angiographic studies of the effect of lipid lowering on the progression of coronary atherosclerosis used different selection criteria and methods to quantify regression and progression, some broad conclusions can be drawn. The studies that used some form of objective quantification of the stenosis and lumen diameter did show some evidence of regression overall but the changes were small in functional terms and achieved statistical significance by virtue of the power and precision of the studies. What is clear is that all the studies whether they use automated quantification or semi-quantified visual grading show evidence for a slowing in progression of the disease. It may be that more aggressive lipid lowering over longer periods will increase angiographic change but the evidence so far does not suggest that diseased vessels will miraculously return to normal or high grade lesions resolve and so avoid the need for angioplasty.
The FATS and POSCH studies were primarily concerned with the angiographic development of the coronary artery disease after lipid lowering but they also examined clinical events. In the large POSCH trial overall mortality caused by coronary heart disease was reduced (deaths overall 62 v 49, p = 0 16; coronary deaths 44 v 32, p = 0 11) but significance was achieved only if death due to coronary disease and non-fatal infarction were combined (125 v 82, p = 0 001).8°In the far smaller FATS trial death caused by coronary disease and acute events such as unstable angina were considered together and were more common in the placebo group (10/52) than in the combined treatment groups (6/94, p = 0 01) representing a reduction in the incidence of clinical events of 73% but with wide confidence limits (23-90%). 81 Evidence that calcium antagonists inhibited the development of atherosclerosis in animals prompted studies of their effect in humans in the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). 82 The aim was to see whether nifedipine could inhibit the progression of angiographically demonstrated disease. The trial was a double blind randomised study of 425 patients, all aged less than 65 with mild disease and an ejection fraction of >0 40. Three hundred and forty eight patients were restudied at three years; 175 were in the placebo group and 173 had been treated with 80 mg of nifedipine daily. The angiograms were quantified by a computer analysis system (CAAS).
An increase in the degree of stenosis by more than 20% in established lesions was equally common in the two groups (9 4% of lesions on placebo, 11 7% on nifedipine). In the controls 4 1% of lesions regressed compared with 3 0% in the nifedipine group. Thus progression or regression of established lesions was not different. Two hundred and forty seven new lesions (including 19 new occlusions) appeared at sites where the angiogram had previously shown an apparently normal vessel. Of these new lesions, 103 occurred in treated patients and 144 in patients in the control group (p < 0 034). In terms of new lesions per patient the average was 0 59 v 0-82-a difference of28%. These results thus suggested that nifedipine can slow the rate at which new atherosclerotic lesions appear on angiography. The study cannot, and never set out to, determine whether this modest reduction in the rate at which new lesions appeared was of any long term benefit to the individual patient. In the study cardiac events and mortality were, however, recorded, and correctly have been reported by the authors. There were eight deaths (three acute myocardial infarction, five sudden cardiac death) in the treated group and two sudden deaths in the controls. patients with coronary atherosclerosis that was demonstrable on angiography were randomised to treatment or placebo.85 Quantification used the CAAS system. When all lesions were analysed irrespective of their initial severity an increase of 10% in diameter stenosis was found in 147 (12-7%) of 1153 lesions in the treated and 170 (14-5%) of 1170 lesions in the control group (NS). In 178 lesions of initially less than 20% of the diameter in the treated group 9-0% progressed compared with 16-3% of the 233 lesions in the control group (p = 0-038). The results based on absolute changes in vessel diameter were similar. The result thus resembled that found in the INTACT trial. There was a positive relation between the inhibition of progression of mild lesions and the lowering of blood pressure. This suggests that control of hypertension might be the simplest explanation for the beneficial effect on lesion progression. In animal models, however, calcium antagonists do not lower blood pressure. So this simple explanation of the beneficial effect is unlikely to be the only one. The clinical event rate was similar in the two groups.
Larger, more complex, and expensive trials are needed to ascertain the influence of calcium antagonists and lipid lowering drugs on the subsequent risk ofcardiac events. Reducing the number of new plaques that appear and preventing further progression should reduce the risk; geographic surveys of atherosclerosis in the human aorta and coronary arteries show that on a population basis the number of plaques, measured as a percentage involvement of the intima, predicts the frequency of acute myocardial infarction and deaths related to atherosclerosis. 86 For all their technical complexity therapeutic trials using angiographic measurement of the development and progression of atherosclerotic lesions have considerable attraction. Because all the subjects in the trial have a measurable variable, differences between two treatment groups can be identified with relatively small numbers. Any result to which the word regression can be applied, albeit to a minor degree, has considerable emotive appeal. In contrast, trials using clinical events and mortality as end points need to be far larger and to last longer for sufficient adverse events to accumulate for comparison. The effects on events and mortality are, however, what we really need to know. However interesting they are in scientific terms, the angiographic studies are not yet a definite surrogate.
A review of all the randornised trials that have so far considered the effect of cholesterol reduction on total mortality87 and coronary heart disease events confirms the original view' that if there is a significant increase in total cholesterol a 1% reduction produces a 2-5% reduction in event rate but a lesser effect on total mortality. There is no difference between primary and secondary trials in this regard and the basic pathology of the disease would not suggest there could be. The trials so far have been concerned with at best modest reductions in plasma lipids: the best recorded in the 19 trials analysed87 is a mean of 17%. These statements are bedevilled by the confusion caused by talking of relative risk reduction when a clearer idea of the magnitude would be given by absolute values. Definitive recommendations for the control of plasma lipid concentrations must await the results of drug trials which produce a more considerable lowering of plasma lipids.
The angiographic studies published do not so far contain any information that should alter, one way or the other, the current therapeutic indications for calcium antagonists, but they are encouraging because they show that the early progresson of atherosclerotic plaques can be modified. Where they are likely to have symptomatic benefit by controlling angina or lowering blood pressure they may also have an additional antiatherogenic effect. The current evidence is an inadequate basis for recommending calcium antagonists outside the previously established indications, though they may ultimately turn out to have other properties as a useful by-product. Definitive recommendations on the role of calcium antagonists as antiatherogenic drugs must be based on the results of further trials designed to evaluate their effect on clinical events.
Methyl xanthine diuretics
Caffeine, theobromine, and theophylline were first studied in 1886 and although they are now obsolete they were important before the discovery of the 
